We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · May 18, 2020

Patients With High-Risk DLBCL Benefit From Dose-Dense Immunochemotherapy Combined With Early Systemic CNS Prophylaxis

Blood advances

 

Additional Info

Blood advances
Patients With High-Risk DLBCL Benefit From Dose-Dense Immunochemotherapy Combined With Early Systemic CNS Prophylaxis
Blood Adv 2020 May 12;4(9)1906-1915, S Leppä, J Jørgensen, A Tierens, L Meriranta, I Østlie, P de Nully Brown, UM Fagerli, TS Larsen, S Mannisto, L Munksgaard, M Maisenhölder, K Vasala, P Meyer, M Jerkeman, M Björkholm, Ø Fluge, S Jyrkkiö, K Liestøl, E Ralfkiaer, S Spetalen, K Beiske, ML Karjalainen-Lindsberg, H Holte

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Brain Cancer Center of Excellence

Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.


Further Reading